WT1 expression at diagnosis does not predict survival in pediatric AML: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1136-1139

  Noronha, Suzie A ^a   Farrar, Jason E ^a   Alonzo, Todd A ^b,c   Gerbing, Robert B ^b   Lacayo, Norman J ^d   Dahl, Gary V ^d   Ravindranath, Yaddanapudi ^e   Arceci, Robert J ^a   Loeb, David M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Acute myeloid leukemia; Prognosis; Prognostic factor; Wilms tumor 1

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE SIZE;

CHILD; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; WT1 PROTEINS;

EID: 71049194464     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22142     Document Type: Article

References (20)

1. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079. (Pubitemid 24328100)
2. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1)mRNAin acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-1225. (Pubitemid 27314159)
3. Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-933. (Pubitemid 39049900)
4. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12: 1886-1894. (Pubitemid 28554462)
5. Schmid D, Heinze G, Linnerth B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643. (Pubitemid 27241240)
6. Spanaki A, Linardakis E, Perdikogianni C, et al. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia. Leuk Res 2007;31:570-572. (Pubitemid 46198930)
7. Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24: 1507-1515. (Pubitemid 46638771)
8. Rodrigues PC, Oliveira SN, Viana MB, et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2007;49:133-138. (Pubitemid 47041101)
9. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AMLtrials conducted between 1981 and 2000. Leukemia 2005;19:2101-2116. (Pubitemid 41741602)
10. O'Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: A report from the Children's Oncology Group Study POG 9421. J Clin Oncol 2008;26:414-420.
11. Siehl JM, Reinwald M, Heufelder K, et al. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2004;83:745-750. (Pubitemid 39485544)
12. -ΔΔCt method. Methods 2001;25:402-408.
13. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89: 1405-1412. (Pubitemid 27080005)
14. Boublikova L, Kalinova M, Ryan J, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: A wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006;20:254-263. (Pubitemid 43148663)
15. Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002;16:1381-1389. (Pubitemid 34893578)
16. Virappane P, Gale RE, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemoresistance in normal karyotype acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 361.
17. Paschka P, Marcucci G, Ruppert AS, et al. Wilms tumor 1 (WT1) gene mutations predict poor outcome in adults with cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 362.
18. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms' tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009;113:5951-5960.
19. Loeb DM, Summers JL, Burwell EA, et al. An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. Leukemia 2003;17:965-971. (Pubitemid 36626325)
20. Inoue K, Tamaki H, Ogawa H, et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998;91:2969-2976. (Pubitemid 28227548)